Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Lisata Therapeutics Inc LSTA

Healthcare Biotechnology
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:LSTA)

Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire November 6, 2025

Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for 'Overall BioPharma Solution of the Year'

GlobeNewswire November 6, 2025

Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent

GlobeNewswire November 4, 2025

Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025

GlobeNewswire October 30, 2025

Lisata Therapeutics to Present at LD Micro Main Event XIX

Newsfile October 13, 2025

Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement

GlobeNewswire October 8, 2025

Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial

GlobeNewswire September 29, 2025

Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire September 2, 2025

Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire August 7, 2025
View More News ››

Opinion & Analysis (NDAQ:LSTA)

Companies flocking to Japan for biotech deals

The Life Sciences Report February 2, 2017
View More Opinion ››

Bullboard Posts (NDAQ:LSTA)

Lisata (LSTA) Surges on Promising Certepetide Data, But Chal

http://beyondspx.com/2024/08/01/lisata-lsta-surges-on-promising-certepetide-data-but-challenges-remain/
MikeTester - August 1, 2024

LSTA about to go live stream

LSTA is presenting at this conference right now! https://2ly.link/1yXNe
Johnthe6 - June 20, 2024

lisata new presentaion

They said Lisata is going to present at this virtual conference! And it’s free! Free register link here: https://buff.ly/4bSLhjm 
Johnthe6 - June 17, 2024

Lisata's new presentation

Seems that Lisata is going to present at this virtual event, And it’s free, Go check this out!  https://buff.ly/4bSLhjm
Johnthe6 - June 5, 2024

news out - CLBS

BASKING RIDGE, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a...
MoneyStock - January 6, 2021

CLBS- 22% up

Good to see that flying.
HugeMoney - December 2, 2020
View more Bullboard ››

Walker Lane Resources Ltd.

Walker Lane Resources Ltd.

Walker Lane Resources Ltd. engages in the acquisition and exploration of mineral properties in Canada. The company explores ...
View More »